ArticleToxicology reports2025
Activation of peroxisome proliferator-activated receptor (PPAR) by pioglitazone in oral traumatic ulcers in female rats.
Article in Toxicology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate the effect of pioglitazone treatment on oral ulcer healing in rats, given its potential to modulate inflammatory processes. Thirty-two animals were randomly allocated into four groups: one control and three treated with different doses of pioglitazone (5, 15, and 45 mg/kg). Oral mucosal ulceration was induced one hour after treatment using a 6 mm diameter and 1 mm deep punch. Samples were collected on days 1, 3, 7, and 14 for histological analysis with optical microscopy, while immunohistochemistry was performed to assess expression of inflammatory markers across five fields. Ulcer size significantly decreased in groups treated with 15 and 45 mg/kg compared with the control group on days 1, 3, and 7. By day 14, no differences were observed between groups, although all groups exhibited progressive reduction from day 7 onward. Histological scoring demonstrated reduced acute inflammation in pioglitazone-treated animals by day 3, evolving into mild inflammation by day 7 and minimal levels by day 14. Additionally, Pioglitazone treatment also reduced TNF-α, IL-6, and NFkB p65 levels compared to controls. This study demonstrates that pioglitazone accelerates oral healing by modulating inflammatory mediators, suggesting a novel therapeutic role in wound management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.